SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
Rhea-AI Summary
SAB Biotherapeutics (Nasdaq: SABS) will release first quarter 2026 financial results on the morning of Tuesday, May 12, 2026 and hold a conference call and webcast at 8:30 AM ET to discuss results and business updates.
Conference dial-in, international number, conference ID 13760144, and a replay will be available under the Investors & Media section at ir.sab.bio.
Positive
- None.
Negative
- None.
News Market Reaction – SABS
In the May 5 session, SABS declined 0.27%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.1% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Clinical data update | Positive | +4.2% | Phase 1 T1D cohort data showing C-peptide preservation and CGM improvements. |
| Apr 15 | Conference data preview | Positive | +4.9% | Plan to present additional SAB-142 clinical and mechanistic data at IDS 2026. |
| Mar 19 | Offering closing | Negative | -0.8% | Closing of $85M underwritten public offering of stock and pre-funded warrants. |
| Mar 17 | Offering pricing | Negative | -9.1% | Pricing of $85M public offering of common stock and pre-funded warrants. |
| Mar 17 | Offering announcement | Negative | -9.1% | Announcement of proposed underwritten offering to fund SAB-142 development and operations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news-driven moves have consistently aligned with the nature of the catalyst: positive clinical/data updates saw gains, while equity offerings saw declines.
Over the past few months, SABS has reported multiple SAB-142 data updates and completed an $85 million equity offering. Clinical and mechanistic data releases in April 2026 were followed by modest gains, while the March 2026 financing sequence (proposed, priced, and closed) coincided with share-price pressure. Against this backdrop, the Q1 2026 earnings call scheduling fits into an ongoing cycle of clinical progress updates and capital-raising to fund SAB-142 development.
Key Terms
anti-thymocyte immunoglobulin medical
type 1 diabetes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.
To access the live conference call, participants may register here.
Conference Details:
Conference Date: Tuesday, May 12, 2026
Conference Time: 8:30 AM ET
Conference Dial-in: 1-877-704-4453
International Dial-in: 1-201-389-0920
Conference ID: 13760144
Conference Call Name: SAB BIO’s Q1 2026 Earnings Call
Following the conference call, a replay of the audio webcast will be available under the Investors & Media section of the Company’s website at ir.sab.bio.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.
CONTACTS
Investors:
Christine Ryan
cryan@sab.bio
Media:
Sheila Carlson
media@sab.bio
